Trial
NCT01689974
Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
NYU Langone Health
Collaborators
—
Condition
Metastatic Melanoma
Intervention
Ipilimumab
Why stopped
Study terminated because PI left institution. Planned Statistical analysis not available
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-02-23